Risk is part of investing. Even the most mature, well-established firms and stocks run the risk of declining to zero. However, that risk is even higher...
Source: Dr. Elemer Piros 10/27/2022 This firm, with eight treatment candidates for mental health disorders in development, boasts a catalyst-rich...
The article Numinus Launches Ketamine Program for Chronic and Serious Illness was originally published on Microdose. Numinus Launches Psychedelic-Assisted...
The founder of two leading psychedelic science companies and an influential nonprofit is shaping research, as well as efforts to patent it. The post...
The article Microdose Announces MindBio Therapeutics as Wonderland 2022 Platinum Sponsor was originally published on Microdose. The leader in the business...
The article Atai Completes Enrollment of Phase 2a Trial for Depression was originally published on Microdose. atai Life Sciences has moved its most advanced...
The article A Deeper Look at Atai Life Sciences’ R&D Day was originally published on Microdose. Today, atai Life Sciences (Nasdaq: ATAI) held its...
More groups are researching the effect of psychedelics on TBI. The post Doctors Look to Psychedelics to Address Concussion Crisis appeared first on Green...
The article Beckley Psytech Acquires Eleusis Therapeutics was originally published on Microdose. Beckley Psytech Strengthens Pipeline and Development...
Privately owned Empyrean Neuroscience, Inc. has launched with a $22 million Series A financing and a genetic engineering platform to advance a pipeline...